progesterone Archives - Revista Brasileira de Ginecologia e Obstetrícia
, , , , Summary
Rev Bras Ginecol Obstet. 2021;43(8):608-615
, , , , To establish a relationship between serum progesterone values on the day of frozen blastocyst transfer in hormone-replaced cycles with the probability of pregnancy, miscarriage or delivery.
This was an ambispective observational study including all frozen-thawed embryo transfer cycles performed at our department following in vitro fecundation from May 2018 to June 2019. The outcomes evaluated were β human chorionic gonadotropin (β-hCG)-positive pregnancy and delivery. Groups were compared according to the level of serum progesterone on the day of embryo transfer: the 1st quartile of progesterone was compared against the other quartiles and then the 2nd and 3rd quartiles against the 4th quartile.
A total of 140 transfers were included in the analysis: 87 with β-HCG>10 IU/L (62%), of which 50 (36%) delivered and 37 had a miscarriage (42%).Women with lower progesterone levels (< 10.7ng/mL) had a trend toward higher β-HCG-positive (72 versus 59%; p>0.05), lower delivery (26 versus 39%; p>0.05) and higher miscarriage rates (64 versus 33%; p<0.01). Comparing the middle quartiles (P25-50) with those above percentiles 75, the rate of pregnancy was similar (60 versus 57%; p>0.05), although there was a trend toward a higher number of deliveries (43 versus 31%; p>0.05) and a lower number of miscarriages (28 versus 45%; p>0.05). These differences were not statistically significant.
There were no differences in pregnancy and delivery rates related with the progesterone level when measured in the transfer day. The miscarriage rate was higher in the 1st quartile group.
Summary
Rev Bras Ginecol Obstet. 2021;43(8):608-615
, , , , To establish a relationship between serum progesterone values on the day of frozen blastocyst transfer in hormone-replaced cycles with the probability of pregnancy, miscarriage or delivery.
This was an ambispective observational study including all frozen-thawed embryo transfer cycles performed at our department following in vitro fecundation from May 2018 to June 2019. The outcomes evaluated were β human chorionic gonadotropin (β-hCG)-positive pregnancy and delivery. Groups were compared according to the level of serum progesterone on the day of embryo transfer: the 1st quartile of progesterone was compared against the other quartiles and then the 2nd and 3rd quartiles against the 4th quartile.
A total of 140 transfers were included in the analysis: 87 with β-HCG>10 IU/L (62%), of which 50 (36%) delivered and 37 had a miscarriage (42%).Women with lower progesterone levels (< 10.7ng/mL) had a trend toward higher β-HCG-positive (72 versus 59%; p>0.05), lower delivery (26 versus 39%; p>0.05) and higher miscarriage rates (64 versus 33%; p<0.01). Comparing the middle quartiles (P25-50) with those above percentiles 75, the rate of pregnancy was similar (60 versus 57%; p>0.05), although there was a trend toward a higher number of deliveries (43 versus 31%; p>0.05) and a lower number of miscarriages (28 versus 45%; p>0.05). These differences were not statistically significant.
There were no differences in pregnancy and delivery rates related with the progesterone level when measured in the transfer day. The miscarriage rate was higher in the 1st quartile group.
Summary
Rev Bras Ginecol Obstet. 2010;32(11):525-529
DOI 10.1590/S0100-72032010001100002
PURPOSE: to evaluate the characteristics of the menstrual cycle and to identify the occurrence of ovulation in nulliparous young women with sickle cell anemia (SCA). METHODS: we conducted a case-control study including 26 nulliparous women of reproductive age, divided into two groups: "cases", consisting of 13 women with SCA, and "Control" Group, consisting of 13 healthy women with the same interval since menarche. The characteristics of the menstrual cycle were reported by the participants, who were also submitted to measurements of serum progesterone, basal body temperature curves and transabdominal ultrasound in three consecutive cycles (total: 78 cycles) in order to identify the occurrence of ovulation. The results were compared between groups using the nonparametric Mann-Whitney or Kruskal Wallis tests, and the differences were considered significant when p-value < 0.05. RESULTS: no significant difference was found in mean chronological age between the two groups (p = 0.2) in the pattern of the menstrual cycle when duration of flow (p = 0.4) and interval between cycles (p = 0.3) were compared. There was no difference between groups in age at menarche (p = 0.05). Mean hemoglobin value was 8.4 g/dL (± 0.9) in the group of women with SCA and 12.6 g/dL (± 0.8) in the control group (p < 0.01). The frequency of ovulatory cycles was similar for cases (76.9%) and controls (92.3%) (p = 0.5), with a predominance of individuals with three ovulatory cycles in the control group (84.6%) compared to 23.1% in the case group (p = 0.04). CONCLUSION: the findings justify the need for effective guidance for patients with SCA regarding sexual activity, the possibility of pregnancy and the alternatives for contraception.
Summary
Rev Bras Ginecol Obstet. 2010;32(11):525-529
DOI 10.1590/S0100-72032010001100002
PURPOSE: to evaluate the characteristics of the menstrual cycle and to identify the occurrence of ovulation in nulliparous young women with sickle cell anemia (SCA). METHODS: we conducted a case-control study including 26 nulliparous women of reproductive age, divided into two groups: "cases", consisting of 13 women with SCA, and "Control" Group, consisting of 13 healthy women with the same interval since menarche. The characteristics of the menstrual cycle were reported by the participants, who were also submitted to measurements of serum progesterone, basal body temperature curves and transabdominal ultrasound in three consecutive cycles (total: 78 cycles) in order to identify the occurrence of ovulation. The results were compared between groups using the nonparametric Mann-Whitney or Kruskal Wallis tests, and the differences were considered significant when p-value < 0.05. RESULTS: no significant difference was found in mean chronological age between the two groups (p = 0.2) in the pattern of the menstrual cycle when duration of flow (p = 0.4) and interval between cycles (p = 0.3) were compared. There was no difference between groups in age at menarche (p = 0.05). Mean hemoglobin value was 8.4 g/dL (± 0.9) in the group of women with SCA and 12.6 g/dL (± 0.8) in the control group (p < 0.01). The frequency of ovulatory cycles was similar for cases (76.9%) and controls (92.3%) (p = 0.5), with a predominance of individuals with three ovulatory cycles in the control group (84.6%) compared to 23.1% in the case group (p = 0.04). CONCLUSION: the findings justify the need for effective guidance for patients with SCA regarding sexual activity, the possibility of pregnancy and the alternatives for contraception.
Summary
Rev Bras Ginecol Obstet. 2010;32(5):229-233
DOI 10.1590/S0100-72032010000500005
PURPOSE: to assess a possible association between polymorphism of the progesterone receptor gene (PROGINS) and recurrent spontaneous abortion (RSA). METHODS: in this case-control study, 85 women with at least three previous spontaneous abortions without an identifiable cause (RSA Group) and 157 women with at least two previous term pregnancies without pathologies and no previous miscarriage (Control Group) were selected. An amount of 10 mL of peripheral blood was collected by venipuncture and genomic DNA was extracted by the DTAB/CTAB method, followed by the polymerase chain reaction (PCR) under specific conditions for this polymorphism and by amplification by 2% agarose gel electrophoresis. The bands were visualized with an ultraviolet light transilluminator and the gels were photographed. Differences in the PROGINS genotype and allele frequencies between groups were analyzed by the χ2 test, with the level of significance set at p<0.05. The Odds Ratio (OR) was also used, with 95% confidence intervals 95%CI. RESULTS: PROGINS genotypic frequencies were 72.3% T1T1 and 27.7% T1T2 for the RSA group and 764% T1T1, 22.3% T1T2 and 1.3% T2T2 for the control group. There were no differecnes between groups when the genotype and allele frequencies were analyzed: respectively p=0.48 (OR: 0.8) and p=0.65 (OR: 0.9). CONCLUSIONS: our results suggest that PROGINS polymorphism is not associated with RSA.
Summary
Rev Bras Ginecol Obstet. 2010;32(5):229-233
DOI 10.1590/S0100-72032010000500005
PURPOSE: to assess a possible association between polymorphism of the progesterone receptor gene (PROGINS) and recurrent spontaneous abortion (RSA). METHODS: in this case-control study, 85 women with at least three previous spontaneous abortions without an identifiable cause (RSA Group) and 157 women with at least two previous term pregnancies without pathologies and no previous miscarriage (Control Group) were selected. An amount of 10 mL of peripheral blood was collected by venipuncture and genomic DNA was extracted by the DTAB/CTAB method, followed by the polymerase chain reaction (PCR) under specific conditions for this polymorphism and by amplification by 2% agarose gel electrophoresis. The bands were visualized with an ultraviolet light transilluminator and the gels were photographed. Differences in the PROGINS genotype and allele frequencies between groups were analyzed by the χ2 test, with the level of significance set at p<0.05. The Odds Ratio (OR) was also used, with 95% confidence intervals 95%CI. RESULTS: PROGINS genotypic frequencies were 72.3% T1T1 and 27.7% T1T2 for the RSA group and 764% T1T1, 22.3% T1T2 and 1.3% T2T2 for the control group. There were no differecnes between groups when the genotype and allele frequencies were analyzed: respectively p=0.48 (OR: 0.8) and p=0.65 (OR: 0.9). CONCLUSIONS: our results suggest that PROGINS polymorphism is not associated with RSA.
Summary
Rev Bras Ginecol Obstet. 2008;30(6):306-311
DOI 10.1590/S0100-72032008000600007
PURPOSE: to investigate the relationship between pain perception (experimental pain threshold and tolerance, in response to ischemia and pressure) in young and healthy young women and female sexual hormone seric levels (estradiol and progesterone). METHODS: 18 volunteers have participated of this study, during three consecutive menstrual cycles. A pressure algometer and a manual dynamometer have been used to measure painful responses to pressure and ischemia algesic stimuli. Blood has been collected for assessment of both hormonal and painful variables, during three menstrual cycles, whose characterization was based on daily oral temperature record, a diary of the menstrual cycles with the onset and end of each cycle, and on estradiol and progesterone plasmatic levels. The average for the algesic variables measured has been compared by analysis of variance (ANOVA) and the Tukey-Kramer's post-test, among the menstrual cycle phases (follicular, periovulatory, early luteal, late luteal and menstrual). The Pearson's test has been used for correlation analysis between algesic and hormonal variables. Statistical significance has been defined as p<0.05. RESULTS: no significant change in pain parameters among the menstrual cycle phases has been observed. Nevertheless, there have been significant negative correlations between progesterone and ischemic threshold (r=-0.23; p<0.01), and pressure tolerance (r=-0.23; p<0.01) at the early luteal phase. CONCLUSIONS: these results indicate that the increase in progesterone levels correlates with a decrease of ischemic threshold and pressure tolerance, suggesting that progesterone plays a role in the pain modulation during the early luteal phase.
Summary
Rev Bras Ginecol Obstet. 2008;30(6):306-311
DOI 10.1590/S0100-72032008000600007
PURPOSE: to investigate the relationship between pain perception (experimental pain threshold and tolerance, in response to ischemia and pressure) in young and healthy young women and female sexual hormone seric levels (estradiol and progesterone). METHODS: 18 volunteers have participated of this study, during three consecutive menstrual cycles. A pressure algometer and a manual dynamometer have been used to measure painful responses to pressure and ischemia algesic stimuli. Blood has been collected for assessment of both hormonal and painful variables, during three menstrual cycles, whose characterization was based on daily oral temperature record, a diary of the menstrual cycles with the onset and end of each cycle, and on estradiol and progesterone plasmatic levels. The average for the algesic variables measured has been compared by analysis of variance (ANOVA) and the Tukey-Kramer's post-test, among the menstrual cycle phases (follicular, periovulatory, early luteal, late luteal and menstrual). The Pearson's test has been used for correlation analysis between algesic and hormonal variables. Statistical significance has been defined as p<0.05. RESULTS: no significant change in pain parameters among the menstrual cycle phases has been observed. Nevertheless, there have been significant negative correlations between progesterone and ischemic threshold (r=-0.23; p<0.01), and pressure tolerance (r=-0.23; p<0.01) at the early luteal phase. CONCLUSIONS: these results indicate that the increase in progesterone levels correlates with a decrease of ischemic threshold and pressure tolerance, suggesting that progesterone plays a role in the pain modulation during the early luteal phase.
Summary
Rev Bras Ginecol Obstet. 1998;20(2):91-95
DOI 10.1590/S0100-72031998000200006
Predicting pregnancy outcome from one or more maternal serum factors has been the subject of numerous investigations with controversial results. The aim of this study was to evaluate the serum levels of CA-125, CA-19.9, CA-15.3, beta-hCG, estradiol, progesterone, alpha-fetoprotein and CEA in women with abortion (n=18) and with pregnancy complicated by bleeding (n=6), in comparison to the serum levels of the control group (n=7). The results showed that the serum levels of CA-125 were significantly increased in the abortion group (153.9 ± 43.3 IU/ml), but no difference was detected in pregnancy complicated by bleeding (17.4 ± 2.6 IU/ml), as compared to control (24.7 ± 13.4 IU/ml). However, high serum levels of CA-19.9 were found in the group with pregnancy complicated by bleeding in comparison with the abortion group (20.2 ± 11.4 IU/ml versus 6.6 ± 1.4 IU/ml, respectively). In relation to hormone serum levels, both, the abortion (17.38 ± 9.4 ng/ml) and bleeding (18.3 ± 8.9 ng/ml) groups showed lower serum levels of progesterone, as compared to control (60.4 ± 26.8 ng/ml). Besides, women with abortion had additional low estradiol serum levels, when compared to controls (1,327 ± 1,015 ng/ml versus 10,774 ± 9,244 ng/ml). It was concluded that the serum levels of progesterone, CA-19.9 and beta-hCG seem to add valuable information to the evaluation of a pregnancy complicated by bleeding.
Summary
Rev Bras Ginecol Obstet. 1998;20(2):91-95
DOI 10.1590/S0100-72031998000200006
Predicting pregnancy outcome from one or more maternal serum factors has been the subject of numerous investigations with controversial results. The aim of this study was to evaluate the serum levels of CA-125, CA-19.9, CA-15.3, beta-hCG, estradiol, progesterone, alpha-fetoprotein and CEA in women with abortion (n=18) and with pregnancy complicated by bleeding (n=6), in comparison to the serum levels of the control group (n=7). The results showed that the serum levels of CA-125 were significantly increased in the abortion group (153.9 ± 43.3 IU/ml), but no difference was detected in pregnancy complicated by bleeding (17.4 ± 2.6 IU/ml), as compared to control (24.7 ± 13.4 IU/ml). However, high serum levels of CA-19.9 were found in the group with pregnancy complicated by bleeding in comparison with the abortion group (20.2 ± 11.4 IU/ml versus 6.6 ± 1.4 IU/ml, respectively). In relation to hormone serum levels, both, the abortion (17.38 ± 9.4 ng/ml) and bleeding (18.3 ± 8.9 ng/ml) groups showed lower serum levels of progesterone, as compared to control (60.4 ± 26.8 ng/ml). Besides, women with abortion had additional low estradiol serum levels, when compared to controls (1,327 ± 1,015 ng/ml versus 10,774 ± 9,244 ng/ml). It was concluded that the serum levels of progesterone, CA-19.9 and beta-hCG seem to add valuable information to the evaluation of a pregnancy complicated by bleeding.
Summary
Rev Bras Ginecol Obstet. 1998;20(9):533-536
DOI 10.1590/S0100-72031998000900007
Purpose: to evaluate the effects of tamoxifen (TAM) on plasma levels of estradiol, progesterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and steroid hormone-binding globulin (SHBG) when given to premenopausal women in the doses of 10 and 20 mg/day for 22 days. Patients and Methods: a randomized double-blind study was performed with 43 premenopausal eumenorrheic women. The patients were divided into three groups: A (N = 15, placebo); B (N = 15, TAM 10 mg/day) and C (N = 13, 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Two hormone determinations were performed, both on the 22nd day of the menstrual cycle: the first in the cycle that preceded the use of the drug and the second, in the following cycle, after 22 days of using the medication. We used the Levine and Student tests in order to evaluate the homogeneity of the sample and the variation of the hormone determinations respectively. Results:serum levels of estradiol, progesterone and SHBG increased significantly in groups B and C. In group C, we also observed increase in serum level of FSH (p < 0.0045) and a fall in prolactin level (p < 0.0055). Conclusions: TAM promoted a significant increase in serum concentrations of estradiol, progesterone and SHBG either in the doses of 10 or 20 mg/day. However, significant increase in FSH and decrease in prolactin were obtained only with the dose of 20 mg/day.
Summary
Rev Bras Ginecol Obstet. 1998;20(9):533-536
DOI 10.1590/S0100-72031998000900007
Purpose: to evaluate the effects of tamoxifen (TAM) on plasma levels of estradiol, progesterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and steroid hormone-binding globulin (SHBG) when given to premenopausal women in the doses of 10 and 20 mg/day for 22 days. Patients and Methods: a randomized double-blind study was performed with 43 premenopausal eumenorrheic women. The patients were divided into three groups: A (N = 15, placebo); B (N = 15, TAM 10 mg/day) and C (N = 13, 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Two hormone determinations were performed, both on the 22nd day of the menstrual cycle: the first in the cycle that preceded the use of the drug and the second, in the following cycle, after 22 days of using the medication. We used the Levine and Student tests in order to evaluate the homogeneity of the sample and the variation of the hormone determinations respectively. Results:serum levels of estradiol, progesterone and SHBG increased significantly in groups B and C. In group C, we also observed increase in serum level of FSH (p < 0.0045) and a fall in prolactin level (p < 0.0055). Conclusions: TAM promoted a significant increase in serum concentrations of estradiol, progesterone and SHBG either in the doses of 10 or 20 mg/day. However, significant increase in FSH and decrease in prolactin were obtained only with the dose of 20 mg/day.
Summary
Rev Bras Ginecol Obstet. 1998;20(5):273-280
DOI 10.1590/S0100-72031998000500007
An open-label comparative study was conducted in nine centers in Brazil to evaluate the tolerability and cycle control of two low-dose oral contraceptives containing 20 mg ethynylestradiol/75 mg gestodene and 20 mg ethynylestradiol/150 mg desogestrel, during six treatment cycles. A total of 167 healthy sexually active women were enrolled (77 in the gestodene group and 90 in the desogestrel group) and 138 completed the six-cycle treatment period. A lipid and hemostatic profile was performed for a subgroup of first users. A total of 867 cycles were evaluated. Irregular bleeding did not occur in 95.4% of the cycles evaluated with gestodene and in 91.9% with desogestrel. Tolerability was good with both preparations but there was significantly more nausea in the desogestrel group. Cycle control was good with both preparations with a significantly lower incidence of irregular bleeding with gestodene when all cycles were considered. There were no clinically significant changes in the hemostatic profile. Lipid profile showed a trend to be more favorable after six cycles of treatment with both preparations. Women in the gestodene group did not present changes in the mean weight; in the desogestrel group there was a significant mean weight increase of 1 kg after six cycles of treatment. Compliance with treatment was good with both preparations. Results of this study demonstrated that low-dose preparations containing gestodene or desogestrel combined with 20 mg of ethynylestradiol are well-tolerated oral contraceptives that provide good cycle control.
Summary
Rev Bras Ginecol Obstet. 1998;20(5):273-280
DOI 10.1590/S0100-72031998000500007
An open-label comparative study was conducted in nine centers in Brazil to evaluate the tolerability and cycle control of two low-dose oral contraceptives containing 20 mg ethynylestradiol/75 mg gestodene and 20 mg ethynylestradiol/150 mg desogestrel, during six treatment cycles. A total of 167 healthy sexually active women were enrolled (77 in the gestodene group and 90 in the desogestrel group) and 138 completed the six-cycle treatment period. A lipid and hemostatic profile was performed for a subgroup of first users. A total of 867 cycles were evaluated. Irregular bleeding did not occur in 95.4% of the cycles evaluated with gestodene and in 91.9% with desogestrel. Tolerability was good with both preparations but there was significantly more nausea in the desogestrel group. Cycle control was good with both preparations with a significantly lower incidence of irregular bleeding with gestodene when all cycles were considered. There were no clinically significant changes in the hemostatic profile. Lipid profile showed a trend to be more favorable after six cycles of treatment with both preparations. Women in the gestodene group did not present changes in the mean weight; in the desogestrel group there was a significant mean weight increase of 1 kg after six cycles of treatment. Compliance with treatment was good with both preparations. Results of this study demonstrated that low-dose preparations containing gestodene or desogestrel combined with 20 mg of ethynylestradiol are well-tolerated oral contraceptives that provide good cycle control.
Summary
Rev Bras Ginecol Obstet. 1998;20(6):309-313
DOI 10.1590/S0100-72031998000600003
Objective: to evaluate variations in body weight, arterial blood pressure, fasting glucose, HbA1C, insulin, total cholesterol, HDL-C, LDL-C, triglycerides, Sgot, SGPT, GGT and bilirubin in women bearing a single subdermal Silastic implant containing 55 mg (+ 10%) of nomegestrol acetate during two years. Methods: eighteen healthy volunteers of reproductive age who desired to use anticonceptive drugs and who did not present contraindications to hormonal contraception participated in the study. All women were investigated before starting treatment and were followed-up for two years. At the end of the first year the capsules were inserted. Results: body weight increased from 54.9 + 1.5 kg at admission to 55.3 + 2.0 kg at 12 months of use (p<0.05) and from 56.0 + 2.7 kg at 24 months of use. There was a slight increase in arterial blood pressure, both systolic and diastolic, at month 12 (p<0.01). At month 24, the arterial blood pressure was not significantly different from the values at admission. All values were within the normal range. Insulin, HbA1C, LDL-C and GGT remained unchanged during the use of the implant. A significant decrease in total cholesterol (p<0.05) was observed in the third month and of HDL-C (p<0.01) in the sixth month. All lipoprotein alterations were inconsistent and values were within the normal range. Significant increases in fast glucose (p<0.05 and p<0.01) were observed in the third and sixth months, respectively. Significant SGOT decreases (p<0.05, p<0.01 and p<0.05) were observed in months 6, 18 and 24, respectively, and of SGPT (p<0.05) in month 18. Significant bilirubin increase (p<0.05) was observed only in the third month of implant use. All these variations remained within the normal range. Conclusions: these results show that, within the normal range, fasting glucose variations do not correlate with alterations in insulin levels. The slight serum lipoprotein, SGTO, SGPT and insulin alterations were transient. No clinical effects could be observed regarding lipoproteins, carbohydrate metabolism, insulin levels and liver function among the users during the two years.
Summary
Rev Bras Ginecol Obstet. 1998;20(6):309-313
DOI 10.1590/S0100-72031998000600003
Objective: to evaluate variations in body weight, arterial blood pressure, fasting glucose, HbA1C, insulin, total cholesterol, HDL-C, LDL-C, triglycerides, Sgot, SGPT, GGT and bilirubin in women bearing a single subdermal Silastic implant containing 55 mg (+ 10%) of nomegestrol acetate during two years. Methods: eighteen healthy volunteers of reproductive age who desired to use anticonceptive drugs and who did not present contraindications to hormonal contraception participated in the study. All women were investigated before starting treatment and were followed-up for two years. At the end of the first year the capsules were inserted. Results: body weight increased from 54.9 + 1.5 kg at admission to 55.3 + 2.0 kg at 12 months of use (p<0.05) and from 56.0 + 2.7 kg at 24 months of use. There was a slight increase in arterial blood pressure, both systolic and diastolic, at month 12 (p<0.01). At month 24, the arterial blood pressure was not significantly different from the values at admission. All values were within the normal range. Insulin, HbA1C, LDL-C and GGT remained unchanged during the use of the implant. A significant decrease in total cholesterol (p<0.05) was observed in the third month and of HDL-C (p<0.01) in the sixth month. All lipoprotein alterations were inconsistent and values were within the normal range. Significant increases in fast glucose (p<0.05 and p<0.01) were observed in the third and sixth months, respectively. Significant SGOT decreases (p<0.05, p<0.01 and p<0.05) were observed in months 6, 18 and 24, respectively, and of SGPT (p<0.05) in month 18. Significant bilirubin increase (p<0.05) was observed only in the third month of implant use. All these variations remained within the normal range. Conclusions: these results show that, within the normal range, fasting glucose variations do not correlate with alterations in insulin levels. The slight serum lipoprotein, SGTO, SGPT and insulin alterations were transient. No clinical effects could be observed regarding lipoproteins, carbohydrate metabolism, insulin levels and liver function among the users during the two years.